Rosetta Genomics Ltd.
ROSG
ROSG was delisted on the 21st of May, 2018.
9 hedge funds and large institutions have $467K invested in Rosetta Genomics Ltd. in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more funds holding
Funds holding: 6 → 9 (+3)
2% more capital invested
Capital invested by funds: $458K → $467K (+$9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$251K |
| 2 |
VF
Virtu Financial
New York
|
+$144K |
| 3 |
Morgan Stanley
New York
|
+$60.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$7.91K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highlander Capital Management
Short Hills,
New Jersey
|
-$20.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $206K | +$60.4K | +34,121 | +21% |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $149K | +$251K | +141,741 | New |
|
|
VF
3
Virtu Financial
New York
| $85K | +$144K | +81,379 | New |
|
|
HCM
4
Highlander Capital Management
Short Hills,
New Jersey
| $22K | -$20.4K | -11,514 | -36% |
|
|
5
UBS Group
Zurich,
Switzerland
| $5K | +$7.91K | +4,469 | +3,575% |
|
|
6
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$4 | +2 | New |
|
ROSG Hedge Fund Activity: Q3 2017 in Review
9 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q3 2017, worth a combined $467K — up 2% from $458K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ROSG positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $251K. The largest seller was Highlander Capital Management, cutting an estimated $20.4K.
- 9 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q3 2017, up from 6 in Q2 2017.
- Funds reported $467K of Rosetta Genomics Ltd. stock for Q3 2017, up 2% quarter-over-quarter.
- 3 funds opened new Rosetta Genomics Ltd. positions in Q3 2017 and 0 closed out, a net change of +3 holders.
- The largest Rosetta Genomics Ltd. buyer in Q3 2017 was Sabby Management, an estimated $251K added.
- The largest Rosetta Genomics Ltd. seller in Q3 2017 was Highlander Capital Management, an estimated $20.4K sold.
Based on aggregated 13F filings for Q3 2017.